Xeris Biopharma Holdings (XERS) Common Equity: 2020-2025
Historic Common Equity for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to -$861,000.
- Xeris Biopharma Holdings' Common Equity rose 96.96% to -$861,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$861,000, marking a year-over-year increase of 96.96%. This contributed to the annual value of -$29.6 million for FY2024, which is 336.67% down from last year.
- Xeris Biopharma Holdings' Common Equity amounted to -$861,000 in Q3 2025, which was up 95.54% from -$19.3 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' Common Equity ranged from a high of $96.5 million in Q1 2022 and a low of -$35.1 million during Q1 2025.
- For the 3-year period, Xeris Biopharma Holdings' Common Equity averaged around -$9.2 million, with its median value being -$9.2 million (2024).
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 2,336.49% in 2022, then crashed by 832.81% in 2024.
- Xeris Biopharma Holdings' Common Equity (Quarterly) stood at $95.2 million in 2021, then crashed by 52.55% to $45.2 million in 2022, then slumped by 115.01% to -$6.8 million in 2023, then plummeted by 336.67% to -$29.6 million in 2024, then soared by 96.96% to -$861,000 in 2025.
- Its Common Equity was -$861,000 in Q3 2025, compared to -$19.3 million in Q2 2025 and -$35.1 million in Q1 2025.